By Dr Adam Jacob Bryant

Conference Abstracts

Garg M; Kureeman MY; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Sureda Balari A; Mielnik M; Nichols M; Mouro J; Khalaf Z; Baig H; Polinkovsky M; Pirooz N; Varghese S; Lee J; Eccersley L; Mateos M-V, 2026, 'DREAMM-7: Long-term responders with belantamab mafodotin (BVd) versus daratumumab (DVd) combinations in relapsed/refractory multiple myeloma', in BRITISH JOURNAL OF HAEMATOLOGY, WILEY, ENGLAND, Liverpool, Vol. 208, pp. S237 - S237, presented at 66th Annual Scientific Meeting of the British-Society-for-Hematology (BSH), ENGLAND, Liverpool, 19 April 2026 - 21 April 2026

Kwan G; Kwan T; Fernando S; Lee F; Lin M; Yun J; Bryant A; Ling S; Toong C, 2026, 'Comparative performance of Freelite and N-Latex serum free light chain assays across a multicentre New South Wales cohort', in Pathology, Elsevier, Vol. 58, pp. s67, http://dx.doi.org/10.1016/j.pathol.2026.01.293

Zhong S; Ashraf MA; Dhir V; Matta L; Bryant A; McEwan A; Watson A-M; Hua M; Ng S; Hsu D; Dunlop L; Hsu H; Sungala N; Motum P; Beaton B, 2026, 'Duffy-null-associated absolute neutrophil count (DANC): an audit from south-western Sydney evaluating the neutrophil lower reference range for patients with DANC', in Pathology, Elsevier, Vol. 58, pp. s64, http://dx.doi.org/10.1016/j.pathol.2026.01.282

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Martinez G; Balarí AS; Mielnik M; Nichols M; Mouro J; Khalaf Z; Baig H; Polinkovsky M; Pirooz N; Varghese S; Lee J; Eccersley L; Mateos M-V, 2025, 'Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma', in Blood, American Society of Hematology, Vol. 146, pp. 2262, http://dx.doi.org/10.1182/blood-2025-2262

Mateos M-V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Martinez G; Balarí AS; Ma J; Ma Y; Nichols M; Mouro J; Khalaf Z; Baig H; Kazeem B; Pirooz N; Varghese S; Lee J; Eccersley L; Hungria V, 2025, 'Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial', in Blood, American Society of Hematology, Vol. 146, pp. 2265, http://dx.doi.org/10.1182/blood-2025-2265

Murali S; Bryant A; Hua M; Sungala N; Motum P; Getta B, 2025, 'EWALL for Elderly Ph- B-ALL: Insights from a South Western Sydney case series', in EWALL for Elderly Ph- B-ALL: Insights from a South Western Sydney case series, Perth, presented at Blood, Perth, 26 October 2025 - 29 October 2025

Ringkowski S; Gration B; McCaughan G; Talam S; King T; Ho P; Bosco A; Yong A; Naidoo S; Wong Doo N; Ling S; Bryant A, 2025, 'Selinexor therapy in multiple myeloma: Implementation of clinical recommendations on use of Selinexor in Australia and review of toxicity and response', in Selinexor therapy in multiple myeloma: Implementation of clinical recommendations on use of Selinexor in Australia and review of toxicity and response, Perth, Australia, presented at Blood, Perth, Australia, 26 October 2025 - 29 October 2025

Bryant A; Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida A; Hajek R; Kim K; Grosicki S; Sia H; Pitombeira de Lacerda M; Garcia E; Balarí A; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos M, 2025, 'DREAMM-7 study of belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in RRMM: efficacy in patients by subsequent therapy', in DREAMM-7 study of belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in RRMM: efficacy in patients by subsequent therapy, Perth, Australia, presented at Blood, Perth, Australia, 26 October 2025 - 29 May 2026

Khalaf Z; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho P; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda M; Martinez G; Balari A; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt M; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M, 2025, 'Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Vd in RRMM: Updates on Overall Survival and Efficacy in DREAMM-7', in BRITISH JOURNAL OF HAEMATOLOGY, WILEY, SCOTLAND, Glasgow, Vol. 206, presented at 65th Annual Scientific Meeting of the British-Society-for-Haematology, SCOTLAND, Glasgow, 27 April 2025 - 29 April 2025

Dimopoulos M; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho P; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda M; Martinez G; Balari A; Sandhu I; Cerchione C; Ganly P; Fu C; Garg M; Abdallah A-O; Gatt M; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; Mckeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M, 2025, 'BELANTAMAB MAFODOTIN plus BORTEZOMIB plus DEXAMETHASONE (BVD) VS DARATUMUMAB plus VD (DVD) IN RRMM: UPDATES ON OVERALL SURVIVAL (OS) AND EFFICACY IN DREAMM-7', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, GREECE, Athens, Vol. 110, pp. 41 - 41, presented at 6th European-Myeloma-Network Meeting, GREECE, Athens, 10 April 2025 - 12 April 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balari AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos V, 2025, 'DREAMM-7 Study of Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Bortezomib plus Dexamethasone in Relapsed/ Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balarí AS; Kazeem B; Pirooz N; Varghese S; Lee J; Baig H; Eccersley L; Robak P; Mateos M-V, 2025, 'PA-475 DREAMM-7 Study of Belantamab Mafodotin + Bortezomib (V) + Dexamethasone (d) vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in Clinical Lymphoma Myeloma & Leukemia, Elsevier, Vol. 25, pp. s321 - s322, http://dx.doi.org/10.1016/s2152-2650(25)03938-2

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Balarí AS; Kazeem B; Lin CP; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Khalaf Z; Mateos M-V, 2025, 'PA-494 Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM', in Clinical Lymphoma Myeloma & Leukemia, Elsevier, Vol. 25, pp. s333 - s334, http://dx.doi.org/10.1016/s2152-2650(25)03957-6

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balarí AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos M-V, 2025, 'POSTER: MM-1049 DREAMM-7 Study of BelantamabMafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in Clinical Lymphoma Myeloma & Leukemia, Elsevier, Vol. 25, pp. s306, http://dx.doi.org/10.1016/s2152-2650(25)01319-9

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Martinez GA; Sureda Balarí AM; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt ME; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Mateos MV, 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial', in Blood, American Society of Hematology, Vol. 144, pp. 772 - 772, http://dx.doi.org/10.1182/blood-2024-200336

Lim KJC; Wellard C; Moore E; Gration B; Augustson B; Mollee P; Zhang J; Doo NW; Ringkowski S; Bryant A; Ninkovic S; Hamad N; McCaughan G; Kumar S; Spencer A; Quach H, 2024, 'Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry', in Blood, American Society of Hematology, Vol. 144, pp. 1951, http://dx.doi.org/10.1182/blood-2024-207609

Hwang A; Kurniawan S; Zhang J; Fani-Molky P; Wong Doo N; Whelan C; King T; Bryant C; Kidson- Gerber G; Bosco A; Parmar G; Lai S; Kwok F; Ling S; Ho P; Bryant A; McCaughan G; Bryant A, 2024, 'Lenalidomide, bortezomib and dexamethasone (RVd) in patients with transplant eligible newly diagnosed multiple myeloma (TE NDMM): final analysis of the NSW Harmonisation study', in Lenalidomide, bortezomib and dexamethasone (RVd) in patients with transplant eligible newly diagnosed multiple myeloma (TE NDMM): final analysis of the NSW Harmonisation study, Brisbane, Australia, presented at BLOOD, 2024, Brisbane, Australia, 27 October 2024 - 30 October 2024

Rasheed F; Ling S; Bryant A; Toong C; Hodgkins C; Taylor M, 2024, 'The use of Mass Spectrometry in the diagnosis and monitoring of plasma cell dyscrasia', in The use of Mass Spectrometry in the diagnosis and monitoring of plasma cell dyscrasia, Brisbane, Australia, presented at BLOOD, 2024, Brisbane, Australia, 27 October 2024 - 30 October 2024

Marivel A-MJ; Roberts TL; Descallar J; Aung WPP; Cheng J; Becker TM; James A; Ma Y; Bryant A; Ling S, 2023, 'Multiple Myeloma in the Culturally and Linguistically Diverse Southwestern Sydney, Australia', in Blood, American Society of Hematology, Vol. 142, pp. 6642, http://dx.doi.org/10.1182/blood-2023-185193

Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S73 - S73, http://dx.doi.org/10.1016/s2152-2650(23)01688-9

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', in Clinical Lymphoma Myeloma & Leukemia, Elsevier, Vol. 23, pp. s196, http://dx.doi.org/10.1016/s2152-2650(23)01907-9

Plesner T; Harrison SJ; Quach H; Lee CH; Bryant A; Vangsted AJ; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Sumiyoshi T; Miller K; Choi E; Schjesvold FH, 2021, 'A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)', in BLOOD, ELSEVIER, GA, Atlanta, Vol. 138, presented at 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), GA, Atlanta, 11 December 2021 - 14 December 2021, http://dx.doi.org/10.1182/blood-2021-147418

McCaughan GJ; Tran S; Durrant S; Harrison SJ; Morton J; Horvath N; Spencer A; Kerridge IH; Er JAK; Barge L; Bryant A; Filshie RJ; Choong E; Lai HC; Tiley C; Mills AK; Butler A; Moore J; Hertzberg M; Kennedy GA; Ho PJ; Sidiqi MH; Bashford J; Routledge D; Taylor K; Lee CH; Kalff A; Xia W; Hamad N, 2020, 'Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', in Blood, American Society of Hematology, Vol. 136, pp. 11 - 12, http://dx.doi.org/10.1182/blood-2020-138991

McCaughan GJ; Verma A; Ling S; Lavee O; Moore J; Bryant A, 2020, 'Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres', in Blood, American Society of Hematology, Vol. 136, pp. 42 - 43, http://dx.doi.org/10.1182/blood-2020-139269

Haack R; Mallik S; Sungala N; Bryant A; Ho LL; Motum P, 2019, 'COPPER DEFICIENCY: DON'T YOU FORGET ABOUT ME.', in INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, WILEY, Vol. 41, pp. 68 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487566000106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Watson A-M; Bryant A; Davison S; Ling S; Levy M, 2016, 'Treatment of Otherwise Ineligible Donors for Hepatitis B Prior to Matched Sibling Allogeneic Stem Cell Transplant', in BONE MARROW TRANSPLANTATION, SPRINGERNATURE, SPAIN, Valencia, Vol. 51, pp. S140 - S140, presented at 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, SPAIN, Valencia, 03 April 2016 - 06 April 2016

Bryant A; Kershaw G; Zebeljan D; Motum P; Das R, 2013, 'Factor VIII inhibitor and pulmonary embolism developing in a patient after meningioma resection: clinical and laboratory aspects', in JOURNAL OF THROMBOSIS AND HAEMOSTASIS, WILEY-BLACKWELL, Vol. 11, pp. 1021 - 1021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331833604400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dalal BI; Al Mugairi A; Bryant A; Lau S; Pi S; Khare NS; Pal J; Mourad YA, 2013, 'Aberrant Expression of Myeloid Antigens Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia Patients with Short Survival', in Transplantation and Cellular Therapy, Elsevier, Vol. 19, pp. s223 - s224, http://dx.doi.org/10.1016/j.bbmt.2012.11.268

Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998-2008', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 118, pp. 1772 - 1772, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011

Bryant AJ; Palma CA; Lutherborrow M; Jayaswal V; Yang YH; Ma D, 2011, 'Knockdown of MicroRNA-10a in Acute Myeloid Leukaemia Cells Bearing the Nucleophosmin1 Mutation Causes Cell Death and Reduced Clonogenicity', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 118, pp. 599 - 600, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299597101636&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Palma CA; Tonna E; Bryaht AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 118, pp. 1044 - 1044, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299597103296&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Palma CA; Tonna E; Bryant AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', in Blood, American Society of Hematology, Vol. 118, pp. 2430, http://dx.doi.org/10.1182/blood.v118.21.2430.2430

Bryant A; Moore J; Dodds A; Milliken S; Fay K; Ma D, 2007, 'Pneumonitis and renal toxicity with sirolimus based GVHD prophylaxis for RIC allogeneic', in HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, FERRATA STORTI FOUNDATION, AUSTRIA, Vienna, Vol. 92, pp. 516 - 516, presented at 12th Congress of the European-Hematology-Association, AUSTRIA, Vienna, 07 June 2007 - 10 June 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000247176901661&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page